Medicamen Biotech (BOM:531146) Other Current Receivables: ₹27 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531146 Medicamen Biotech Ltd BOM:531146
63 GF Score
Price ₹246.10
GF Value ₹513.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicamen Biotech Other Current Receivables?

Medicamen Biotech BOM:531146 +0.57% 63 Other Current Receivables is ₹27 Mil as of Mar. 2026. GuruFocus rates BOM:531146 with a GF Score™ of 63/100 and a GF Value™ of ₹513.27 (Possible Value Trap). The stock has 4 warning signs investors should review.

Medicamen Biotech's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹27 Mil.

Medicamen Biotech's quarterly Other Current Receivables declined from Sep. 2025 (₹26.68 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹26.63 Mil).

Medicamen Biotech's annual Other Current Receivables increased from Mar. 2024 (₹21.81 Mil) to Mar. 2025 (₹25.12 Mil) and increased from Mar. 2025 (₹25.12 Mil) to Mar. 2026 (₹26.63 Mil).

Medicamen Biotech Other Current Receivables Related Terms

Medicamen Biotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Medicamen Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Biotech Other Current Receivables Chart

Medicamen Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.37 25.15 21.81 25.12 26.63

Medicamen Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.12 0.00 26.68 0.00 26.63
BOM:531146
63GF Score
Medicamen Biotech Ltd BOM:531146
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicamen Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹27 Mil mean?
Medicamen Biotech (BOM:531146) has a Other Current Receivables of ₹27 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Medicamen Biotech and its competitors.
Is Medicamen Biotech's Other Current Receivables too high?
Medicamen Biotech's current Other Current Receivables is ₹27 Mil. Overall, Medicamen Biotech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicamen Biotech's Other Current Receivables compare to ZTS?
Medicamen Biotech's Other Current Receivables of ₹27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Medicamen Biotech and its competitors. Medicamen Biotech's current Other Current Receivables is ₹27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicamen Biotech (BOM:531146) is currently considered Possible Value Trap. The stock's GF Value™ is ₹513.27, compared to a current price of ₹246.10 — trading 52.1% below its estimated fair value. The current Other Current Receivables is ₹27 Mil. Medicamen Biotech's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Medicamen Biotech (BOM:531146), the current Other Current Receivables is ₹27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicamen Biotech (BOM:531146) Overvalued in 2026?

Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued. The current stock price of ₹246.10 is trading 52.1% below its estimated GF Value™ of ₹513.27. GuruFocus considers Medicamen Biotech to be Possible Value Trap.

Key valuation signals for BOM:531146:

  • Other Current Receivables: ₹27 Mil
  • GF Value™: ₹513.27 vs. price of ₹246.10 (52.1% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicamen Biotech Business Description

Other Exchanges MEDICAMEQ:India
Address 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
63GF Score

Get the complete analysis for BOM:531146

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹246.10
Price
₹513.27
GF Value